Ryogen LLC Is Awarded Patent For Polynucleotides Related To Tumor-Suppressing Subtransferable Candidate 4
6/24/2014 10:25:34 AM
SUFFERN, N.Y.--(BUSINESS WIRE)--Ryogen LLC, a genomics R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded a new patent, bringing the total number of U.S. Patents issued to Ryogen to 30.
U.S. Patent No. 8,722,865, titled “Isolated genomic polynucleotide fragments from p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4),” is the first Ryogen patent to be issued after the seminal Myriad decision of the U.S. Supreme Court that clarified the patentability of genomic constructs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by